大麻在管理炎症性肠病方面的潜力及其未来前景
Arsalan Rauf1, Mudassar Nisar2, Muhammad Shaeel1
1Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Cureus
|December 3, 2024
概括
大麻通过与CB1和CB2受体相互作用,显示出炎症性肠病 (IBD) 症状缓解的潜力. 然而,需要更多的大规模试验来确认其在IBD管理中的有效性和安全性.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩氏病和性结肠炎,涉及胃肠道炎症.
- 目前的IBD治疗包括传统疗法,对大麻作为一种补充治疗越来越感兴趣.
- 大麻素与肠道和免疫系统中的CB1和CB2受体相互作用,影响机动性,分泌和炎症.
研究的目的:
- 审查有关大麻在治疗炎症性肠病方面的有效性和安全性的现有证据.
- 确定进一步研究的需要,特别是大规模的随机对照试验.
主要方法:
- 对IBD患者大麻使用的观察性和安慰剂对照试验的综述.
- 对大麻素受体相互作用 (CB1和CB2) 和它们在胃肠道上的生理影响的分析.
主要成果:
- 大麻表明IBD的潜在症状益处,包括肠道运动和炎症的减少.
- 现有的研究通常具有小样本大小,限制了关于大麻在IBD中的有效性和安全性的最终结论.
结论:
- 虽然有希望,但目前的证据不足以将大麻作为标准IBD治疗方法.
- 大规模的,随机的,安慰剂对照试验,标准化大麻素配方和长期随访是必不可少的.
- 未来的研究应该探索大麻衍生品和内分泌素,以优化治疗效果和最小化IBD的副作用.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
316
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
316
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119


